[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100254767":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":26,"centralContacts":38,"locations":47,"responsibleParty":207,"collaborators":209,"id":212,"slug":213,"hasResults":214,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":214,"sex":220,"minAge":221,"maxAge":222,"enrollmentInfo":223,"targetDuration":10,"studyType":226,"phases":10,"briefSummary":227,"conditions":228,"keywords":233,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":244},{"fullName":5,"class":6},"Erasme University Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"High risk",null,"Conditioning therapy for bone marrow transplantation or pelvic irradiation. Fertility preservation is usually already proposed in this group of patients. No intervention.",[13],"Other: No intervention",{"label":15,"type":10,"description":16,"interventionNames":17},"Moderate\u002Flow risk","Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML (Acute myeloide leukemia), osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL (acute lymphoblastic hormone), Wilms tumour, retinoblastoma.\n\nThis is the study group we will compare with high risk and no risk patients. No intervention",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"No risk","Patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.\n\nNo intervention",[13],[23],{"type":6,"name":24,"description":24,"armGroupLabels":25,"otherNames":10},"No intervention",[9,15,19],[27,31,35],{"name":28,"affiliation":29,"role":30},"Isabelle Demeestere, PhD","Erasme ULB- Belgium","STUDY_DIRECTOR",{"name":32,"affiliation":33,"role":34},"Alina Ferster","Queen Fabiola children's university hospital- Belgium","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":37,"role":34},"Christine Decanter","CHRU Lille, France",[39,43],{"name":28,"role":40,"phone":41,"phoneExt":10,"email":42},"CONTACT","+32 2 555 65 92","idemeest@ulb.ac.be",{"name":44,"role":40,"phone":45,"phoneExt":10,"email":46},"Julie Dechene","+32 2 555 63 58","jdechene@ulb.ac.be",[48,69,85,104,117,131,147,162,180,193],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Centre Hospitalier Chrétien (CHC)- Clinique de l'espérance","RECRUITING","Montegnée","Liège","4420","Belgium","BE",{"type":57,"coordinates":58},"Point",[59,60],5.51411,50.64576,{"lat":60,"lon":59},[63,67],{"name":64,"role":40,"phone":65,"phoneExt":10,"email":66},"Morgan Collin","+32 4 224 91 42","morgan.collin@chc.be",{"name":68,"role":34,"phone":10,"phoneExt":10,"email":10},"Nadine Francotte",{"facility":70,"status":50,"city":71,"state":10,"zip":72,"country":54,"countryCode":55,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Universitair Ziekenhuis Antwerpen","Antwerp","2650",{"type":57,"coordinates":74},[75,76],4.40026,51.22047,{"lat":76,"lon":75},[79,83],{"name":80,"role":40,"phone":81,"phoneExt":10,"email":82},"Hanna Ryckaert","+32 3 821 58 39","hanna.ryckaert@uza.be",{"name":84,"role":34,"phone":10,"phoneExt":10,"email":10},"Joris Verlooy",{"facility":86,"status":50,"city":87,"state":10,"zip":88,"country":54,"countryCode":55,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Hôpital Universitaire Reine Fabiola (HUDERF)","Brussels","1020",{"type":57,"coordinates":90},[91,92],4.34878,50.85045,{"lat":92,"lon":91},[95,99,103],{"name":96,"role":40,"phone":97,"phoneExt":10,"email":98},"Merry Vanpuyvelde","+32 2 477 38 85","merry.vanpuyvelde@huderf.be",{"name":100,"role":40,"phone":101,"phoneExt":10,"email":102},"Bernard Wenderickx","+32 2 477 36 54","bernard.wenderickx@huderf.be",{"name":32,"role":34,"phone":10,"phoneExt":10,"email":10},{"facility":105,"status":50,"city":87,"state":10,"zip":106,"country":54,"countryCode":55,"cosmosGeoPoint":107,"geoPoint":109,"contacts":110},"Universitair Ziekenhuis Brussels","1090",{"type":57,"coordinates":108},[91,92],{"lat":92,"lon":91},[111,115],{"name":112,"role":40,"phone":113,"phoneExt":10,"email":114},"Wiert Robberechts","+32 2 801 28 14","Wiert.Robberechts@uzbrussel.be",{"name":116,"role":34,"phone":10,"phoneExt":10,"email":10},"Jutte Van der Werff",{"facility":118,"status":119,"city":120,"state":10,"zip":10,"country":54,"countryCode":55,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"UZ-Gent","NOT_YET_RECRUITING","Ghent",{"type":57,"coordinates":122},[123,124],3.71667,51.05,{"lat":124,"lon":123},[127,130],{"name":128,"role":40,"phone":10,"phoneExt":10,"email":129},"Els Vandecruys","Els.Vandecruys@uzgent.be",{"name":128,"role":34,"phone":10,"phoneExt":10,"email":10},{"facility":132,"status":50,"city":133,"state":10,"zip":134,"country":54,"countryCode":55,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Universitair Ziekenhuis Leuven","Leuven","3000",{"type":57,"coordinates":136},[137,138],4.70093,50.87959,{"lat":138,"lon":137},[141,145],{"name":142,"role":40,"phone":143,"phoneExt":10,"email":144},"Jemima Gaytant","+32 16 34 37 63","jemima.gaytant@uzleuven.be",{"name":146,"role":34,"phone":10,"phoneExt":10,"email":10},"Anne Uyttebroeck",{"facility":148,"status":50,"city":52,"state":10,"zip":149,"country":54,"countryCode":55,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Centre Hospitalier Régional (CHR)-Citadelle","4000",{"type":57,"coordinates":151},[152,153],5.56749,50.63373,{"lat":153,"lon":152},[156,160],{"name":157,"role":40,"phone":158,"phoneExt":10,"email":159},"Catherine Sondag","+32 4 321 89 77","Catherine.Sondag@chrcitadelle.be",{"name":161,"role":34,"phone":10,"phoneExt":10,"email":10},"Caroline Piette",{"facility":163,"status":50,"city":164,"state":10,"zip":165,"country":166,"countryCode":167,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"Centre Oscar Lambret","Lille","59000","France","FR",{"type":57,"coordinates":169},[170,171],3.05512,50.63391,{"lat":171,"lon":170},[174,178],{"name":175,"role":40,"phone":176,"phoneExt":10,"email":177},"Sandy Vandermeersch","+33 3 20 29 58 26","s-vandermeersch@o-lambret.fr",{"name":179,"role":34,"phone":10,"phoneExt":10,"email":10},"Hélène Sudour-Bonnange",{"facility":181,"status":50,"city":164,"state":10,"zip":182,"country":166,"countryCode":167,"cosmosGeoPoint":183,"geoPoint":185,"contacts":186},"CHRU Lille-Hôpital Jeanne de Flandre","59037",{"type":57,"coordinates":184},[170,171],{"lat":171,"lon":170},[187,191],{"name":188,"role":40,"phone":189,"phoneExt":10,"email":190},"Cécile Veron","+33 3 20 44 60 58","cecile.veron@chru-lille.fr",{"name":192,"role":34,"phone":10,"phoneExt":10,"email":10},"Benedicte Bruno",{"facility":194,"status":119,"city":195,"state":10,"zip":10,"country":166,"countryCode":167,"cosmosGeoPoint":196,"geoPoint":200,"contacts":201},"Hôpital Robert Debré","Paris",{"type":57,"coordinates":197},[198,199],2.3488,48.85341,{"lat":199,"lon":198},[202,205],{"name":203,"role":40,"phone":10,"phoneExt":10,"email":204},"Jean-Hugue Dalle","jean-hugues.dalle@rdb.aphp.fr",{"name":206,"role":34,"phone":10,"phoneExt":10,"email":10},"Jean- Hugue Dalle",{"type":208,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[210],{"name":211,"class":6},"Queen Fabiola Children's University Hospital","100254767","amh-as-a-predictor-of-infertility-risk-in-children-with-cancer-chance-100254767",false,"NCT02595255","AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)","Antimüllerian Hormone as a Predictor of Future Infertility Risk in Prepubertal\u002FPubertal Cancer Patients","CHANCE","Inclusion Criteria:\n\n* Patients from 3 to 14 year old included - Belong to one of these 3 groups (modified from Wallace et al, 2005):\n\n  * High risk : Conditioning therapy for bone marrow transplantation or pelvic irradiation\n  * Moderate\u002FLow risk : Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML, osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL, Wilms tumour, retinoblastoma.\n  * No risk (control group) : patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.\n\nExclusion Criteria:\n\n* CNS (central nervous system) irradiation, cerebral tumour\n* Current or previous ovarian disease\u002Fsurgery\n* Familial history of premature ovarian failure (no iatrogenic or surgical origins)\n* Previous known severe chronic disease potentially affecting normal growth or puberty (diseases inducing malnutrition, anorexia, genetic\u002Fcongenital disorders as Turner, Kallman, BPES(Blepharophimosis, ptosis, and epicanthus inversus syndrome) syndromes, uncontrolled severe diabetes, Cushing Syndrome, auto-immune diseases, cystic fibrosis, severe renal dysfunction)\n* Genetic\u002Fcongenital disorders inducing mental retardation","FEMALE","3 Years","14 Years",{"count":224,"type":225},275,"ESTIMATED","OBSERVATIONAL","While most of the children spontaneously recover menstruation or experienced normal puberty after chemotherapy, their ovarian reserve may be impaired by treatment inducing future infertility. Fertility preservation is currently proposed for selected prepubertal patients with a high risk of premature ovarian failure after treatment (mostly conditioning regimen for bone marrow transplantation). For patients with low or moderate risks, counselling is very difficult and no fertility preservation procedure is usually proposed for these patients as no marker of the ovarian reserve has been validated in this young population to assess the individual risk.\n\nThe primary objective of the study is to prevent long-term treatment-related infertility by detecting the young patients who normally progressed to menarche but have a reduced ovarian reserve. These patients may benefit from particular follow-up and fertility preservation procedure.",[229,230,231,232],"Fertility Preservation","Lymphoma","Pediatrics Cancer","Gonadotropin-releasing Hormone Agonist",[234],"chemotherapy\u002FGnRH (gonadotropin-releasing hormone) analogues\u002Flymphoma\u002Fchildren\u002Ffertility","2020-04-30",{"date":237,"type":238},"2020-05-04","ACTUAL",{"date":240,"type":238},"2014-04",{"date":242,"type":225},"2036-12",{"name":5,"class":6},10]